Role of Curcumin in Paclitaxel Induced PN

Sponsor

Ain Shams University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05966441

Collaborator

(none)

Enrollment

Arms

6.3

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Paclitaxel induced peripheral neuropathy is the most common and serious side effect associated with Paclitaxel treatment in breast cancer patients receiving Paclitaxel.

The efficacy of antioxidant molecules as neuroprotective strategies to preventing the development of peripheral neuropathy has been investigated in preclinical and clinical studies. Vitamin E and Glutathione have been explored as adjuvant therapies to preventing taxane-induced peripheral neuropathy. Other tested neuroprotective treatments with limited success include amifostine, glutamine and acetyl l-carnitine. Curcumin's antioxidant capacity is similar to other potent antioxidants, such as trolox (a vitamin E analog). Curcumin inhibits lipid peroxidation in different tissues, regulates intracellular levels of antioxidant enzymes (e.g., catalase, glutathione peroxidase and superoxide dismutase) and is an effective intracellular reactive oxygen species (ROS) scavenger.

The investigators are going to investigate the neuroprotective effect of Curcumin against Paclitaxel induced peripheral neuropathy.

Condition or Disease	Intervention/Treatment	Phase
Chemotherapy-induced Peripheral Neuropathy	Dietary Supplement: Curcumin Drug: Paclitaxel	Phase 2

Detailed Description

The work is a prospective, randomized, open label controlled study. A total of 90 breast cancer female patients will be enrolled in the study. Eligible patients will simply be randomized using random allocation generator, after the end of anthracycline adjuvant therapy to one of two groups, Group I: will receive paclitaxel regimen plus 2g of curcumin Group II: will receive paclitaxel regimen only.

The cases involved in the study will be recruited from Ain Shams Teaching Hospital.

All patients presenting to the department were assessed for eligibility according to certain inclusion and exclusion criteria.

Details of the research steps that the subscriber will be exposed to:

Base line evaluation then alignment in either intervention or control group either for taking the interventional drug or standard of care in control group.
Blood samples will be collected at baseline.
Patient will be given a weekly supply of the medication and will be asked to take his prescribed dose daily.
Every week all patients will be asked about their symptoms and if they experience any adverse drug reaction.
Patients will receive the interventional drug until the last paclitaxel dose will be taken.
After 3 months, another full clinical examination and blood sample will be obtained.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

80 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Details of the research steps that the subscriber will be exposed to: Base line evaluation then alignment in either intervention or control group either for taking the interventional drug or standard of care in control group. Blood samples will be collected at baseline. Patient will be given a weekly supply of the medication and will be asked to take his prescribed dose daily. Every week all patients will be asked about their symptoms and if they experience any adverse drug reaction. Patients will receive the interventional drug until the last paclitaxel dose will be taken. After 3 months, another full clinical examination and blood sample will be obtained.Details of the research steps that the subscriber will be exposed to:Base line evaluation then alignment in either intervention or control group either for taking the interventional drug or standard of care in control group. Blood samples will be collected at baseline. Patient will be given a weekly supply of the medication and will be asked to take his prescribed dose daily. Every week all patients will be asked about their symptoms and if they experience any adverse drug reaction. Patients will receive the interventional drug until the last paclitaxel dose will be taken. After 3 months, another full clinical examination and blood sample will be obtained.

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

Evaluating the Effect of Curcumin in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients

Anticipated Study Start Date :

Aug 30, 2023

Anticipated Primary Completion Date :

Dec 15, 2023

Anticipated Study Completion Date :

Mar 10, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Experimental group Patients will receive their Paclitaxel-based chemotherapy along with Curcumin at a dose of oral 2g daily till the end of chemotherapy.	Dietary Supplement: Curcumin The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders. Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress. Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily Drug: Paclitaxel Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV.. Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV.
Placebo Comparator: Control group Patients will receive their Paclitaxel-based chemotherapy only	Dietary Supplement: Curcumin The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders. Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress. Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily Drug: Paclitaxel Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV.. Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV.

Arm

Intervention/Treatment

Experimental: Experimental group

Patients will receive their Paclitaxel-based chemotherapy along with Curcumin at a dose of oral 2g daily till the end of chemotherapy.

Dietary Supplement: Curcumin

The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders. Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress. Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily

Drug: Paclitaxel

Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV.. Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV.

Placebo Comparator: Control group

Patients will receive their Paclitaxel-based chemotherapy only

Dietary Supplement: Curcumin

Drug: Paclitaxel

Outcome Measures

Primary Outcome Measures

Evaluate the effect of Curcumin on the incidence and severity of paclitaxel-induced peripheral neuropathy (PIPN) in breast cancer patients. [Baseline]
After each cycle, initial evaluation of response will be done guided by clinical examination and functional assessment and questionnaire.
Evaluate the effect of Curcumin on the damage of nerve fibers induced by paclitaxel. [Baseline]
Nerve growth factor level will be obtained at day 0 and at the end of the paclitaxel course

Secondary Outcome Measures

Evaluate the effect of adding curcumin to paclitaxel-based chemotherapy on response rate in neoadjuvant therapy. [baseline]
CT scan will be done before first dose of paclitaxel and at the end of the course

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Clinical diagnosis of early stage breast cancer with age > 18 years.
Performance status of the patients based on Eastern Cooperative Oncology Group (ECOG) from 0 to 2.
Patients must receive paclitaxel 80 mg/m2 weekly or 175 mg/m2 every 3 weeks for 12 weeks.
Patients clinical parameters should be (ANC ≥ 1500/mm3). Platelet count 100,000/mm3) (serum total bilirubin < 1.5 mg/dl) and (creatinine < 1.5 mg/dl).

Exclusion Criteria:

Patients they had any signs and symptoms of clinical neuropathy.
Diabetes mellitus
Patients receiving vitamin supplementation including vitamin B1, B6 and B12
Patients receiving antidepressants, anticoagulants, opioids or anticonvulsants
Patients had a hypersensitivity to curcumin.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Ain Shams University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:

Ain Shams University

ClinicalTrials.gov Identifier:

NCT05966441

Other Study ID Numbers:

Paclitaxel induced PN

First Posted:

Jul 28, 2023

Last Update Posted:

Jul 28, 2023

Last Verified:

Jul 1, 2023

Studies a U.S. FDA-regulated Drug Product:

Yes

Studies a U.S. FDA-regulated Device Product:

Product Manufactured in and Exported from the U.S.:

Yes

Keywords provided by Ain Shams University

Paclitaxel

Curcumin

Breast Cancer

Additional relevant MeSH terms:

Peripheral Nervous System Diseases

Curcumin

Paclitaxel

Study Results

No Results Posted as of Jul 28, 2023